As patients start chemotherapy to treat their cancer, they are educated on the side effects, particularly neutropenia, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
As patients start chemotherapy to treat their cancer, they are educated on the side effects, particularly neutropenia, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
Transcript
How are patients educated on the risk of neutropenia when they’re treated for cancer?
Any patient coming to Florida Cancer Specialists does education prior to starting or on the day of starting their chemotherapy, but there are many that are oral patients that maybe don’t ever go into a treatment room.
So, our care management department helps manage all of those patients, and with that we talk about the side effects of chemotherapy, with neutropenia being one of the most potentially lethal to them. So, we talk about those precautions and we sort of have templates built, as well as patients calling in after hours, and we have a neutropenia protocol that we follow, as well.
ASCO GU Posters Address Cost-Effectiveness, Implementation Barriers for New mUC Treatments
February 13th 2025Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into practice due to high costs and a lack of targeted initiatives to aid health care providers with integration.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More
Study Finds Declining SCLC Incidence, but Stagnant Survival Rates
February 7th 2025SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more effective treatments.
Read More